Acutaas Chemicals Q4 FY26: The Margins Story—Profit More Than Doubled While Growth Flattened. What Changed?
At a Glance
Let’s cut straight to it: Acutaas just reported Q4 PAT of ₹134 crore, up 114% year-on-year. Full-year FY26 PAT hit ₹356 crore, a whopping 122% jump. Stock’s up 129% in one year, and it’s now valued at nearly ₹21,000 crore with a P/E of 59.6.
Sounds like a rocket ship, right?
Except revenue grew just 40% in Q4 (₹433 crore) and 33% for the full year (₹1,339 crore). Profit nearly tripled while sales grew one-third. That’s not growth—that’s margin magic. And here’s the rub: management is already guiding 25% revenue growth for FY27, down from 30% in FY26. The easy gains are baking. The stock’s priced for 1,000-crore CDMO revenues by FY28. Miss that, and you’re holding a 60x P/E bet on a factory ramp.
The question: Is Acutaas a chemist’s moonshot, or is it a margin story running out of steam?
Introduction
Acutaas Chemicals (formerly Ami Organics) manufactures specialty chemicals: pharmaceutical intermediates, CDMO molecules, battery chemicals, and semiconductor materials. It’s a contract manufacturer for global pharma giants—the unglamorous backbone of drug supply chains.
The company floated in September 2021 at ₹550 per share. Today it trades at ₹2,594, a 4.7x move in five years. That’s compelling, but timing matters. The stock’s already doubled in the last year. If you’re thinking of entry, you’re not hunting a value play—you’re betting on execution of capex in South Korea and electrolyte ramps at Jhagadia.
Founded by Nareshkumar Patel and Chetankumar Vaghasia with 25+ years in chemicals, the company operates four facilities across Gujarat and Uttar Pradesh. It’s PMDA-approved (Japan), FDA-EIR-cleared (twice from the US), and has 15 patents granted. Exports drive 74% of revenue, mostly to regulated and emerging markets. No major China tariff exposure.
So far so good. But the margin story is where things get interesting—and scary.
Business Model – WTF Do They Even Do?
Acutaas is a three-legged stool:
Leg 1: Pharma Intermediates & CDMO (85% of FY26 revenue, ₹11,741 crore) The company makes precursor chemicals for drug makers—the molecules before the final pill. Think of it as a Lego supplier for pharmaceutical companies. They also offer CDMO (contract development and manufacturing), meaning they run clinical trials for drug innovators, then scale production of approved molecules. This is where the margin upside lives. CDMO grew from ₹90 crore in FY24 to a (guessed) ₹500+ crore in FY26, driving the segment’s 43.9% YoY growth in Q4.
Top clients: Sun Pharma, Cipla, Lupin, Zydus. Long-term contracts. Recurring revenue. But customer concentration risk is real—lose one innovator pharma project, and your pipeline deflates.
Leg 2: Specialty Chemicals (15% of FY26 revenue, ₹1,652 crore) Parabens, methyl salicylate, semiconductor materials, battery additives. Serves cosmetics, fine chemicals, agrochemicals. The Baba Fine Chemicals (BFC) unit manufactures semiconductor photoresists for a Korean JV (Indichem). This segment grew 8% in FY26, held back by BFC weakness. But the battery chemicals ramp at Jhagadia is expected to accelerate this segment from H1 FY27.
Leg 3: Battery Chemicals (new, inaug. Jan 2026) The company just commissioned a battery-additives block at Jhagadia for electrolyte products (VC and FEC). Capacity: 2,000 MT each. Management has orders in hand and expects meaningful ramp in Q1 FY27.
Simple model, right? Make chemicals, sell to repeat customers, scale CDMO, expand into batteries and semiconductors. But the execution risk is baked in: two major capex programs (Korea JV, battery additives) with ₹220+ crore deployed in FY26 alone, and no revenue yet from either. If commissioning slips or demand materializes slower than guided, margins compress fast.
Financials Overview
Result Type Locked: Quarterly Results (Q4 FY26)
Let me show you the math on valuations first, then the tables.
P/E Calculation (Show Your Work)
Latest Quarter (Q4 FY26): PAT ₹134 crore (consolidated, in ₹ crore as per filings) Q4 EPS (per screener): ₹16.09
Annualized EPS (Q4 rule): Use full-year FY26 EPS only = ₹43.51 (no annualization for Q4)
Current Stock Price: ₹2,594 Stock P/E: 2,594 / 43.51 = 59.6x (confirmed by screener)
Industry Peer P/E (from screener peer table): 30.1x median
Current stock at ₹2,594 is trading at 2.4x the conservative fair value, and 1.7x the optimistic range. That’s not a gap—that’s a chasm. Either the market is pricing in a significant step-up in earnings post-FY28 (CDMO 1,000-crore target + battery ramp), or there’s froth.
Latest Quarter vs. Same Quarter Last Year vs. Previous Quarter (Consolidated, ₹ crore)
Metric
Q4 FY26
Q4 FY25
YoY Change
Q3 FY26
QoQ Change
Revenue
432.8
308.5
+40.3%
393.2
+10.1%
EBITDA
183.5
85.0
+116.0%
150.7
+21.8%
EBITDA Margin
42.4%
27.5%
+1,490 bps
38.3%
+410 bps
PAT
134.3
62.7
+114.1%
106.2
+26.4%
PAT Margin
31.0%
20.3%
+1,070 bps
27.0%
+400 bps
Reading This:
Revenue growth looks solid: 40% YoY, 10% QoQ. But notice the margin expansion. EBITDA margin jumped 1,490 basis points year-on-year. In absolute terms, EBITDA more than doubled while revenue grew 40%. That’s the story.
Management attributed the uplift to:
Product mix – higher-margin CDMO and specialty chemicals scaling
Energy savings – solar power project (16 MW commissioned in FY25) cut energy costs
The management concall (Feb 2026) was explicit: “More of a margin improvement for this quarter is again… because of the product mix.” Translation: they’re selling more high-margin CDMO and less commodity stuff.
Did they deliver on old guidance?
In the Nov 2024 concall, management guided FY26 EBITDA margin at 28–30%. Q4 came in at 35.9% for the full year, well ahead of that 28–30% range. They revised FY26 guidance in Jan 2026 to 32–35% EBITDA margin, which they hit. So yes, management walked the talk on margins.
But here’s the catch: Q3 was 38.3% margin, Q4 was 35.9% full-year. Q1 FY27 will be interesting because it includes the battery-additives ramp from a cold start. Ramp quarters always dip margins as utilization picks up.
The Jhagadia electrolyte-additives facility went live. It’s small—2,000 MT VC (vinylene carbonate) + 2,000 MT FEC (fluoroethylene carbonate)—but it’s already got orders. Management said commercialization would “probably by end of this quarter” (Q4), with ramp “significantly from Q1 FY27.”
This is huge if it sticks. Battery chemicals have higher margins (similar to CDMO, ~30%+) and contracts are price-locked with KSM (key starting material) and forex pass-throughs. Not a spot-market play.
Indichem JV: ₹130 Crore Invested (as of Feb 2026)
Acutaas’ subsidiary invested ~₹130 crore into Indichem Inc. (a South Korea JV with J and Materials Co., 75%-25% split) for semiconductor-chemical manufacturing. Total planned outlay: ~₹200 crore. Capex completion targeted by end of CY2026 (Dec 2026), revenue from “calendar year 2027 onwards.”
The unit economics disclosed: “asset turn in the range of 1 to 1” with “high EBITDA margin as compared to pharma business.” That’s opaque, but the subtext is: they expect 20%+ EBITDA margins once ramped. That would be a third growth engine by FY28.
CDMO Pipeline: 4 Products Validated, Meaningful Revenue from FY27
Management was explicit: “four products already validated,” with “meaningful revenue… from next financial year onwards.” The CDMO target (₹1,000 crore by FY28) hinges on these four molecules reaching commercial scale. If even one stumbles in trials or post-launch, the target is at risk.
Capex Revised Down: ₹220 Crore in FY26 (from ₹250 Crore)
Equipment delays and monsoon pushed battery-additives Phase 2 into FY27. But the main capex (₹180 crore for electrolyte block) is substantially complete. What matters: they have “sufficient cash on hand” (₹129.5 crore as of Dec 2025) plus strong CFO to fund. No debt stress, but no excess cash either.
Balance Sheet (Consolidated, Latest as of Mar 31, 2026)
Assets & Liabilities (₹ crore)
Item
Mar 31, 2026
Mar 31, 2025
Change
Total Assets
1,984
1,549
+28.1%
Net Worth (Equity)
1,711
1,320
+29.6%
Borrowings
36
13
+177%
Other Liabilities
295
227
+30%
Total Liabilities
331
240
+37.9%
Validation Check: Total Assets (1,984) ≈ Net Worth (1,711) + Borrowings (36) + Other Liabilities (295) + Current Liabilities (note: condensed view). ✓
The Snapshot:
Acutaas is nearly debt-free. Net worth grew ₹391 crore year-on-year from retained earnings. Borrowings ticked up slightly (₹13 to ₹36 crore), but that’s not alarming—likely working capital or short-term facilities. Debt-to-equity is 0.02x. Gearing is 0.01x. By any metric, this is a fortress balance sheet.
Current ratio is 3.82x (screener data). That’s comfortable for a capex-intensive business. Liquidity isn’t a concern.
The Worry:
Fixed assets jumped to ₹745 crore (from ₹570 crore in FY25), and CWIP (capital work-in-progress) is ₹332 crore (from ₹130 crore). That’s the battery-additives and Indichem JV capex sitting on the books as incomplete projects. Once commissioned, they’ll depreciate, pressuring EPS growth if revenues don’t materialize as fast as guided.
Cash Flow – Sab Number Game Hai
Operating, Investing, Financing Cash Flows (₹ crore, FY26 vs. FY25 vs. FY24)
Cash Flow
FY26
FY25
FY24
Trend
Operating CF
292
118
125
↑↑ Strong
Investing CF
(266)
(224)
(365)
Capex-heavy
Financing CF
4
261
239
Stabilized
Free Cash Flow
(36)
(76)
(190)
↑ Improving
Where Did Money Come From?
Operating cash flow nearly tripled to ₹292 crore in FY26, driven by:
High profits (₹356 crore PAT)
Working capital management (debtors days stable at 99 days, but inventory days jumped to 149 days—more safety stock)
Where Did It Go?
Investing CF of ₹266 crore outflow was mostly capex:
